How to Spot the Halo Effect in Your Investments

Why do the world's most experienced investors often hand over millions to founders who have nothing but a PowerPoint? It often happens because the halo effect creates a mental shortcut that bypasses critical thinking during due diligence.

Investing is rarely a purely logical process because we're wired to look for signals of success rather than raw data. When a famous name backs a project, we assume the technology is sound because we respect the person who signed the check.

Why the Halo Effect Blinds Sophisticated Investors

This cognitive bias occurs when our overall impression of a person influences how we feel and think about their character or competence in specific, unrelated areas. In John Carreyrou’s Bad Blood, he documents how Elizabeth Holmes used her associations with powerful men to silence technical doubts.

Because figures like Don Lucas and Larry Ellison were involved, observers assumed the Theranos technology was revolutionary. Carreyrou notes that by its third round of funding, the company reached a valuation of $165 million purely on the strength of these associations.

Investors didn't feel the need to look under the hood because the "halo" of Silicon Valley royalty provided a sense of security. If the man who groomed the founder of Oracle says a startup is the future, most people stop asking to see the actual lab results.

Borrowing Authority Through Famous Billionaires

Elizabeth Holmes was a master of using investment psychology to her advantage. She cultivated a board that included Henry Kissinger, George Shultz, and James Mattis to create an aura of untouchable authority.

These men had spent decades in the highest levels of government and military service. Their presence on the board suggested a level of ethics and oversight that simply didn't exist inside the company’s laboratory.

Carreyrou explains that Holmes also meticulously emulated the style of Steve Jobs, from the black turtlenecks to the intense, unblinking stare. This aesthetic choice reinforced the halo effect by making her look like a proven winner before she had shipped a single working product.

Overvaluing Pedigree Over Performance

When evaluating founders, investors often fall into the trap of prioritizing "pedigree"—where a person went to school or who their mentor is. Holmes used her Stanford connection and her relationship with Professor Channing Robertson to validate her early claims.

Because Robertson was a star faculty member, his endorsement acted as a technical shield. Investors saw a Stanford-backed prodigy rather than a nineteen-year-old dropout with a scientifically impossible idea.

Data from the book shows that Theranos presented a slide deck to Walgreens and Safeway claiming six deals with five companies would generate $120 million to $300 million in revenue. These projections were accepted largely because of the prestige of the people presenting them.

Ignoring Red Flags Amid Hype

The halo effect causes a psychological phenomenon where we interpret evidence to fit our existing positive narrative. When Henry Mosley, the Theranos CFO, pointed out that the technology wasn't reliable, he was fired for not being a "team player."

Instead of investigating his claims, the board and investors saw Mosley as the problem. They were so enamored with the vision of the "iPod of healthcare" that they viewed any technical failure as a minor hurdle rather than a systemic fraud.

This bias is so powerful that it survived years of internal failure. Carreyrou mentions that the company raised $32 million in its third round despite the fact that their primary demo in Switzerland relied on a faked result beamed from California.

Famous Names and Phantom Technology

The most prominent example of this bias is the relationship between Don Lucas and Elizabeth Holmes. Lucas had taken Oracle public and his reputation was the foundation of the Theranos valuation.

When Larry Ellison occasionally dropped by the office in his red Porsche, it sent a signal to employees and potential partners that the company was a winner. These visual cues reinforced the idea that questioning the technology was synonymous with questioning the smartest people in the world.

Another example is General James Mattis. His belief that the finger-stick technology could save soldiers on the battlefield led him to pressure military regulators. He was so caught in the halo of Holmes's vision that he ignored the warnings of Lieutenant Colonel David Shoemaker.

Filter the Founder Hype

Evaluating a high-growth startup requires stripping away the names and looking at the mechanics of the business. You can protect your capital by following three specific habits when a deal feels too good to be true.

1. Audit the board for relevant technical expertise. A board filled with former diplomats and generals is a red flag if the company is building medical hardware. Demand to see directors who have actually built and scaled similar technology in the same industry.

2. Request independent, third-party verification of all core claims. Never rely on data provided by the company or their celebrity backers. Ask for peer-reviewed studies or allow your own independent expert to conduct a trial of the product in a controlled environment.

3. Evaluate the founder’s transparency with their own team. High turnover among senior executives or a culture of extreme compartmentalization often indicates a gap between the public halo and the internal reality. Speak to former employees about whether the technology they built actually matches the marketing materials.

Why Technical Skepticism Is Vital

Critics of this approach argue that early-stage investing is inherently about betting on people. They claim that being too skeptical can cause you to miss out on visionary founders who are simply moving faster than the industry expects.

In Silicon Valley, "fake it till you make it" is often seen as a legitimate strategy for building momentum. However, the Theranos case proves that there's a hard line between aspirational marketing and delivering faulty medical results that endanger lives.

Ignoring your own technical questions because you're intimidated by a founder’s famous backers is a failure of fiduciary duty. A prestigious board is never a substitute for a working product that delivers accurate data.

Investing on the strength of a board's prestige rather than the product’s performance leads to catastrophic losses. Success in a portfolio is measured by the accuracy of the underlying assets, not the fame of the people in the room. Remove one investment from your watchlist today that you only like because of its celebrity backers.